Antibiotics designed with generative AI against gonorrhea and MRSA
Over 36 million possible compounds were screened computationally: candidate NG1 killed resistant Neisseria gonorrhoeae in a dish and in a mouse model, while DN1 cleared a MRSA skin infection in mice. Only 2 of 80 fragment candidates could be synthesized; these are preclinical results.
Technology: Generative AI for molecule design
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Generative models screened more than 10^7 chemical fragments in silico against N. gonorrhoeae or S. aureus, plus unconstrained design. Of 24 synthesized compounds, seven showed selective antibacterial activity; two leads reduced bacterial burden in mouse infection models.
- Still unknown: Mouse results only; no human testing is stated. The paper's abstract was read, not the full text.
- AI role: Genetic algorithms and variational autoencoders generated fragment-based and de novo compounds; researchers synthesized and tested selected compounds.
Evidence sources: https://www.cell.com/cell/abstract/S0092-8674(25)00855-4
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: press release. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Original institutional announcement checked for the specific results, AI contribution and limitations cited in the antibiotic dossier or mathematical follow-up pilot. Full-paper reanalysis, external replication and an exhaustive follow-up search were not performed..
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 127 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
Directed relationships from this entry; they do not merge catalog counts.
- 2020-02-halicin · extends: The source names this earlier screening result as program background for moving to de novo generative design. New compounds and experiments; not a clinical follow-up or replication of the earlier candidate. Source
- 2023-05-abaucina · extends: The source names this earlier screening result as program background for moving to de novo generative design. New compounds and experiments; not a clinical follow-up or replication of the earlier candidate. Source